As of the latest Form 4 filed Jul 13, 2026.
What Jupiter Neurosciences, Inc. Common Stock insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 30 most recent filings for JUNS.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-07-13 | 2026-03-02 | Hayward Marshall A. Chief Scientific Officer | MExercise | +225K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Kampf Julie B. Director | MExercise | +82.9K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Rosen Alexander Gustaf Erik Chief Administrative Officer | MExercise | +96.6K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Rosen Alexander Gustaf Erik, Chief Administrative Officer | MExercise | +165K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Hayward Marshall A. Chief Scientific Officer | MExercise | +399K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Hayward Marshall A., Chief Scientific Officer | MExercise | +390K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Hemmerly Nicholas H. Director | MExercise | +95.5K | — | — | No | Form 4 ↗ |
| 2026-07-13 | 2025-06-02 | Weis Holger Director | MExercise | +85.8K | — | — | No | Form 4 ↗ |
| 2025-07-07 | 2025-06-02 | Elmasri Saleem CFO and Secretary | MExercise | +66.3K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | Silva Alison D. Pres + Chief Business Officer | PPurchase | +100.00 | $1.05 | $104.96 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +250.00 | $1.04 | $259.20 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +250.00 | $1.03 | $257.50 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +250.00 | $1.02 | $255.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +100.00 | $1.02 | $101.68 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER CEO and Chairman | PPurchase | +1.00K | $1.05 | $1.05K | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER, CEO and Chairman | PPurchase | +1.50K | $1.04 | $1.56K | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER, CEO and Chairman | PPurchase | +700.00 | $1.03 | $721.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER, CEO and Chairman | PPurchase | +1.45K | $1.02 | $1.48K | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER, CEO and Chairman | PPurchase | +2.00K | $1.01 | $2.02K | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-30 | ROSEN CHRISTER, CEO and Chairman | PPurchase | +1.00K | $0.98 | $980.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-27 | Silva Alison D. Pres + Chief Business Officer | PPurchase | +250.00 | $1.05 | $262.50 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-27 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +250.00 | $1.04 | $260.88 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-27 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +100.00 | $1.04 | $103.50 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-27 | Silva Alison D., Pres + Chief Business Officer | PPurchase | +250.00 | $1.00 | $250.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-27 | ROSEN CHRISTER CEO and Chairman | PPurchase | +166.00 | $1.06 | $175.96 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-02 | Silva Alison D. Pres + Chief Business Officer | MExercise | +110K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-02 | ROSEN CHRISTER CEO and Chairman | MExercise | +476K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-07-01 | 2025-06-02 | ROSEN CHRISTER, CEO and Chairman | MExercise | +497K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2025-01-24 | 2025-01-22 | Weis Holger Director | MExercise | +10.8K | — | — | No | Form 4 ↗ |
| 2025-01-24 | 2025-01-22 | Brady Allison W Director | MExercise | +21.8K | — | — | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also JUNS’s full analysis or the market-wide insider trading feed. The tabs above jump to JUNS’s other SEC data.
Source: SEC Form 4 filings for JUNS, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.